Raven focuses her practice on corporate and securities law, capital markets transactions, corporate finance, and general corporate matters. She has experience drafting documents for public and private securities offerings, special purpose acquisition company (SPAC) offerings, and mergers and acquisitions. She also performs due diligence, assists clients with SEC filing and reporting obligations, and counsels companies on corporate governance issues. Raven works with public and private companies in a variety of industries, including life sciences, technology, and health care.
Prior to joining Mintz, Raven was an associate at a New York City–based boutique corporate and securities law firm, where she worked on corporate transactions and advised clients on SEC compliance and corporate governance matters. Earlier, she was a legal intern in the New York office of a Chinese corporate law firm.
During law school, Raven served as a summer legal intern with a full-service law firm in Beijing, China and a clerk in a public prosecutor’s office in Beijing.
viewpoints
SEC Issues New Statement on Cybersecurity Incident Disclosure
June 3, 2024 | Alert | By Daniel T. Kajunski, Anne Bruno, Cynthia Larose, Raven Sun
Read about a recent statement from Erik Gerding, Director of the SEC’s Division of Corporation Finance, which provided clarification regarding the disclosure of cybersecurity incidents by reporting companies.
SEC Adopts Amendments to Section 13 Reporting Requirements
October 25, 2023 | Alert | By Anne Bruno, Daniel T. Kajunski, Raven Sun
Read about the SEC’s amendments to the rules, adopted on October 10, 2023, governing beneficial ownership reporting under Sections 13(d) and 13(g) of the Securities Exchange Act of 1934.
SEC Approves NYSE and Nasdaq Compensation “Clawback” Listing Standards; Compliance Required by December 1, 2023
June 23, 2023 | Alert | By Anne Bruno, Daniel T. Kajunski, Raven Sun
Read about the executive compensation recovery “clawback” listing standards proposed by the NYSE and Nasdaq, the consequences for failing to meet these requirements, and the steps affected issuers should take to ensure compliance by the December 1 deadline.
News & Press
Mintz Advises Aspen Aerogels on $98M Follow-on Offering
November 19, 2024
Mintz advised Aspen Aerogels, Inc. (NYSE: ASPN), a technology leader in sustainability and electrification solutions, on a registered follow-on offering of 4,887,500 shares of its common stock, which included 637,500 shares pursuant to the underwriters’ option to purchase additional shares of its common stock. The price to the public in the offering was $20.00 per share and the gross proceeds to Aspen from the offering were approximately $98 million, before deducting underwriting discounts and commissions and estimated offering expenses.
Mintz Advises ArriVent BioPharma on $175M Nasdaq IPO
February 01, 2024
Mintz Members John Rudy and Matthew T. Simpson led the team that advised ArriVent Biopharma, Inc. on its initial public offering (IPO) on the Nasdaq Global Market. This was the second biotech IPO of 2024. ArriVent is a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics.
Mintz's interdisciplinary team continues its leadership role in life sciences, serving as legal counsel to ProKidney LP in its $2.6 billion SPAC merger, and its subsequent listing on the Nasdaq under the ticker symbol "PROK". ProKidney is a leading clinical-stage cellular therapeutics company focused on chronic kidney disease. ProKidney's lead product candidate is in Phase 3 clinical development and has the potential to slow, stabilize and reverse decline in kidney function
Recent Insights
Mintz advised Aspen Aerogels, Inc. (NYSE: ASPN), a technology leader in sustainability and electrification solutions, on a registered follow-on offering of 4,887,500 shares of its common stock, which included 637,500 shares pursuant to the underwriters’ option to purchase additional shares of its common stock. The price to the public in the offering was $20.00 per share and the gross proceeds to Aspen from the offering were approximately $98 million, before deducting underwriting discounts and commissions and estimated offering expenses.
SEC Issues New Statement on Cybersecurity Incident Disclosure
June 3, 2024| Alert|
Mintz Members John Rudy and Matthew T. Simpson led the team that advised ArriVent Biopharma, Inc. on its initial public offering (IPO) on the Nasdaq Global Market. This was the second biotech IPO of 2024. ArriVent is a clinical-stage company dedicated to accelerating the global development of innovative biopharmaceutical therapeutics.
